A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow us to keep up to date. The Most Read Articles of 2021: COVID-19 01- Efficacy of the Sinopharm Vaccine Against COVID-19 Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced…
Reasons Behind Increased COVID-19 Infections in a Highly Vaccinated Population
In December 2020, the healthcare workforce at San Diego University saw an unexpected increase in COVID-19 infections. Concurrently, this same month, one of the most ambitious vaccination campaigns ever was taking off, one which managed to inoculate 76% of the population by March 2021 and 87% by June same year. Infections saw a significant reduction…
SOLACI-CACI 2021 | Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic
✔️ Watch again the session on Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic in the SOLACI-CACI 2021 Congress. 👨🏫 Program: 04:55 – Thromboembolic Complications in COVID – José Ceresetto 27:59 – Global Registry of Acute Myocardial Infarction of Primary PCI in COVID Era – Giuseppe De Luca 53:36 – Infectious Disease Care in…
Primary COVID-19 Infection Protects Against Potential Reinfection?
These study outcomes suggest reinfection is relatively rare in patients who recover from COVID-19. In addition, natural immunity against SARS-CoV-2 persists for at least one year and offers similar protection to that reported by vaccines. These data were obtained from cases infected with the original virus. For now, we do not know if it also…
Efficacy of Mass Vaccination with Pfizer/BioNTech against COVID-19 in Israel
We need to know how effective vaccines are by population subgroup outside the controlled setting of a clinical trial. Israel was one of the first countries to deploy a nationwide mass vaccination strategy. This is why it results ideal to compare its results against clinical trial results. All subjects receiving the BNT162b2 mRNA Covid-19 Vaccine…
Asymptomatic Patients: The Key to Understand the Prevalence of the COVID-19 Pandemic
This study recently published in JAMA showed that asymptomatic individuals infected with COVID-19 account for more than half of all instances of disease transmission. This finding is key to direct resources in the right direction to manage the pandemic until safe and effective vaccines are available and widely used. Severe acute respiratory syndrome coronavirus 2…
Safety and Efficacy of the Pfizer-BioNTech Vaccine Against COVID-19
The NEJM has published the efficacy of the COVID-19 vaccine developed by Pfizer and BioNTech, featuring slight differences in the age of enrollment and endpoint definitions compared with other vaccines. Similarly to Moderna‘s, this vaccine is composed of a lipid nanoparticle with modified RNA that encodes a spike glycoprotein covering the surface, modified by two…
Efficacy of the Moderna COVID-19 Vaccine
With the results of the main vaccines published in leading journals, summarizing each of them is relevant in order to inform our patients. Considering the differences in efficacy, safety, logistics, and subjective confidence according to the origin of each of them, having robust information to provide informed advice was a must. Today, we will analyze…
Natural History of Asymptomatic COVID-19 Infection
Information on the natural history of asymptomatic infection with the new coronavirus (COVID-19) remains scarce. We are just beginning to understand what happens with patients with severe disease. The outbreak of COVID-19 on the cruise ship Diamond Princess provided a unique opportunity to study contacts and patients with asymptomatic infection within a closed population. This…
Efficacy of Remdesivir against COVID-19
This final report published in NEJM about the efficacy of remdesivir against COVID-19 infection vs placebo showed its superiority though only in soft end points, which does not seem to modify the course of this pandemic. Multiple drugs initially promising have been shown ineffective against the new virus. The case of hydroxychloroquine resulted paradigmatic: not…